Janssen Search
Search results
Our Vision
Human Microbiome Institute Human Microbiome Institute Microbial artwork credit: Mehmet Berkmen, Ph.D. and Maria Peñil A New Paradigm For Health Solutions Vast Potential Applications A Collaborative Model Join Our Team We are seeking curious, ...
Our Approach
Human Microbiome Institute Human Microbiome Institute Microbial artwork credit: Mehmet Berkmen, Ph.D. and Maria Peñil Solving Industry Challenges The Microbiome in Action Let’s Work Together Join Our Team We are seeking curious, resourceful, and ...
Johnson & Johnson spotlights nipocalimab at FMF Congress 2024 – the first and only FcRn blocker to be studied in maternal fetal diseases
Jun 27, 2024 The Phase 3 AZALEA and Phase 3 FREESIA clinical studies are enrolling pregnant individuals who are at risk for severe HDFN and FNAIT These rare and potentially life-threatening alloantibody diseases affecting pregnant individuals and their ...
Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
May 25, 2023 United States The Librexia program evaluating milvexian is unrivaled as the most comprehensive factor XIa inhibitor clinical development program to date and will provide extensive data from nearly 50,000 patients, with all three studies ...
Clinical Trials: Against All Odds
A Janssen leader’s reflections on 'Clinical Trials: Against All Odds' Clinical trials are a hugely complex enterprise that depend on the expertise, organization and dedication of many scientists, engineers, clinicians, project managers and ...
Partnering in Neuroscience
Partner With Janssen in Neuroscience We believe that partnerships are essential to drive change, innovation and transformation, and we are committed to ensuring the success of our collaborations. Our global presence and cross-business portfolio provide us ...
Meet Our Immunology Affiliates
Our Affiliates in Immunology Janssen Research & Development partners closely with other organizations within the Janssen Pharmaceutical Companies of Johnson & Johnson to ensure that the scientific advances from our immunology pioneers reach the ...
Teri L. Lawver
TERI L. LAWVER WORLDWIDE VICE PRESIDENT IMMUNOLOGY Teri Lawver is Worldwide Vice President for the Immunology Therapeutic Area with Janssen Pharmaceutical Companies of Johnson & Johnson. Together with the Immunology Research & Development ...
WCLC 2021
--> Welcome to the Janssen Oncology WCLC Virtual Newsroom At the Janssen Pharmaceutical Companies of Johnson & Johnson, our commitment to patients, caregivers and clinicians goes beyond medicine. Our goals are big. We aim to eliminate cancer. ...
Biomarkers in Oncology
Biomarkers We are pursuing the era of personalized medicine through biomarkers. The Importance of Biomarkers Biomarkers are an increasingly important component of our drug development activities, and they are used in multiple ways. We see enormous ...